Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spero Therapeutics (SPRO) Other Operating Expenses (2022 - 2025)

Spero Therapeutics (SPRO) has disclosed Other Operating Expenses for 4 consecutive years, with $587000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Operating Expenses changed N/A year-over-year to $587000.0, compared with a TTM value of $587000.0 through Sep 2025, changed N/A, and an annual FY2023 reading of $5.3 million, down 37.96% over the prior year.
  • Other Operating Expenses was $587000.0 for Q3 2025 at Spero Therapeutics, down from $5.3 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $8.6 million in Q4 2022 and bottomed at -$49000.0 in Q3 2022.
  • Average Other Operating Expenses over 3 years is $3.6 million, with a median of $2.9 million recorded in 2023.
  • Peak annual rise in Other Operating Expenses hit 10930.61% in 2023, while the deepest fall reached 10930.61% in 2023.
  • Year by year, Other Operating Expenses stood at $8.6 million in 2022, then tumbled by 37.94% to $5.3 million in 2023, then tumbled by 88.94% to $587000.0 in 2025.
  • Business Quant data shows Other Operating Expenses for SPRO at $587000.0 in Q3 2025, $5.3 million in Q3 2023, and $8.6 million in Q4 2022.